DeuterOncology is a clinical-stage drug development company. Its lead product, DO-2, is a deuterated MET kinase inhibitor that is brain penetrant and is being developed as a potential ‘best in class’ targeted therapy for MET driven disease. MET-inhibitors shows success in NSCLC however these treatments are hindered by the toxic…
Read More